Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation-Reference-Cited by-同舟云学术

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation

Published:2020-12-10 Issue:4 Volume:86 Page:490-495
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Perez-Valero Ignacio,Llibre Josep M.,Castagna Antonella,Pulido Federico,Molina Jean-Michel,Esser Stefan,Margot Nicolas,Shao Yongwu,Temme Lauren,Piontkowsky David,McNicholl Ian R.,Haubrich Richard

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference30 articles.

1. Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana;Martin-Odoom;Virol J.,2018

2. Comparisons of primary HIV-1 drug resistance between recent and chronic HIV-1 infection within a sub-regional cohort of Asian patients;Kiertiburanakul;PLoS One.,2013

3. Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China;Wang;BMC Infect Dis.,2019

4. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies;Hamers;Clin Infect Dis.,2012

5. Accumulation of HIV-1 drug resistance mutations after first-line immunological failure to evaluate the options of recycling NRTI drugs in second-line treatment: a study from South India;Sivamalar;AIDS Res Hum Retrov.,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current drugs for HIV-1: from challenges to potential in HIV/AIDS;Frontiers in Pharmacology;2023-10-26

2. Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV: a multicenter cohort study;AIDS Research and Therapy;2023-01-03

3. Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome;Chinese Medical Journal;2022-12-28

4. Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells;Clinical Microbiology Reviews;2022-12-21

5. Discovery of benzyloxyphenyl- and phenethylphenyl-imidazole derivatives as a new class of ante–drug type boosters;Bioorganic & Medicinal Chemistry Letters;2022-09